{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T06:27:37Z","timestamp":1791959257067,"version":"4.3.4"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/j.jpba.2015.12.026","type":"journal-article","created":{"date-parts":[[2015,12,22]],"date-time":"2015-12-22T18:47:59Z","timestamp":1450810079000},"page":"322-332","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["Quantitative analysis of maytansinoid (DM1) in human serum by on-line solid phase extraction coupled with liquid chromatography tandem mass spectrometry - Method validation and its application to clinical samples"],"prefix":"10.1016","volume":"120","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3125-4639","authenticated-orcid":false,"given":"Olivier","family":"Heudi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Barteau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Picard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Kretz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2015.12.026_bib0005","doi-asserted-by":"crossref","first-page":"15","DOI":"10.4161\/mabs.27436","article-title":"Antibody-drug conjugates","volume":"6","author":"Beck","year":"2013","journal-title":"mAbs"},{"key":"10.1016\/j.jpba.2015.12.026_bib0010","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.coph.2005.04.017","article-title":"Drug-conjugated monoclonal antibodies for the treatment of cancer","volume":"5","author":"Lambert","year":"2005","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.jpba.2015.12.026_bib0015","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1038\/nbt1141","article-title":"Arming antibodies: prospects and challenges for immunoconjugates","volume":"23","author":"Wu","year":"2005","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jpba.2015.12.026_bib0020","doi-asserted-by":"crossref","first-page":"9280","DOI":"10.1158\/0008-5472.CAN-08-1776","article-title":"Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate","volume":"68","author":"Lewis Phillips","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.jpba.2015.12.026_bib0025","doi-asserted-by":"crossref","first-page":"8620","DOI":"10.1158\/1078-0432.CCR-04-1134","article-title":"Potent and specific antitumor efficacy of CMC-544, a CD22-targeted immunoconjugate of calicheamicin, against systemically disseminated B-cell lymphoma","volume":"10","author":"DiJoseph","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jpba.2015.12.026_bib0030","first-page":"3736","article-title":"The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease","volume":"62","author":"Wahl","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.jpba.2015.12.026_bib0035","doi-asserted-by":"crossref","first-page":"5620","DOI":"10.1021\/jm025540g","article-title":"Tumor-specific novel taxoid-monoclonal antibody conjugates","volume":"45","author":"Ojima","year":"2002","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jpba.2015.12.026_bib0040","doi-asserted-by":"crossref","first-page":"201","DOI":"10.4155\/bio.12.299","article-title":"Bioanalytical assay strategies for the development of antibody-drug conjugate biotherapeutics","volume":"5","author":"Kaur","year":"2013","journal-title":"Bioanalysis"},{"key":"10.1016\/j.jpba.2015.12.026_bib0045","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1158\/1078-0432.843.11.2","article-title":"In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate","volume":"11","author":"Sanderson","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jpba.2015.12.026_bib0050","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1200\/JCO.2003.05.137","article-title":"Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study","volume":"21","author":"Tolcher","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jpba.2015.12.026_bib0055","doi-asserted-by":"crossref","first-page":"901","DOI":"10.2174\/138920012802138598","article-title":"Catabolic fate and pharmacokinetic characterization of trastuzumab emtansine (T-DM1): an emphasis on preclinical and clinical catabolism","volume":"13","author":"Shen","year":"2012","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.jpba.2015.12.026_bib0060","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.taap.2013.09.003","article-title":"Preclinical safety profile of trastuzumab emtansine (T-DM1): mechanism of action of its cytotoxic component retained with improved tolerability","volume":"273","author":"Poon","year":"2013","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.jpba.2015.12.026_bib0065","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ijms.2011.05.010","article-title":"A sensitive LC\u2013MS\/MS method for the determination of free maytansinoid DM4 concentrations\u2014method development, validation, and application to the nonclinical studies of antitumor agent DM4 conjugated hu-anti-Cripto MA b B3F6 (B3F6-DM4) in rats and monkeys","volume":"312","author":"Wei","year":"2012","journal-title":"Int. J. Mass Spectrom."},{"key":"10.1016\/j.jpba.2015.12.026_bib0070","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1177\/0091270011403742","article-title":"Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer","volume":"52","author":"Gupta","year":"2012","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.jpba.2015.12.026_bib0075","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1200\/JCO.2010.29.5865","article-title":"Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy","volume":"29","author":"Burris","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jpba.2015.12.026_bib0080","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2009.26.2071","article-title":"Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer","volume":"28","author":"Krop","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jpba.2015.12.026_bib0085","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jpba.2008.09.041","article-title":"The use of partially porous particle columns for the routine, generic analysis of biological samples for pharmacokinetic studies in drug discovery by reversed-phase ultra-high performance liquid chromatography\u2013tandem mass spectrometry","volume":"49","author":"Mallett","year":"2009","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2015.12.026_bib0090","doi-asserted-by":"crossref","first-page":"4200","DOI":"10.1021\/ac800205s","article-title":"Towards absolute quantification of therapeutic monoclonal antibody in serum by LC\u2013MS\/MS using isotope-labeled antibody standard and protein cleavage isotope dilution mass spectrometry","volume":"80","author":"Heudi","year":"2008","journal-title":"Anal. Chem."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708515302910?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708515302910?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T07:51:21Z","timestamp":1692172281000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708515302910"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":18,"alternative-id":["S0731708515302910"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2015.12.026","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quantitative analysis of maytansinoid (DM1) in human serum by on-line solid phase extraction coupled with liquid chromatography tandem mass spectrometry - Method validation and its application to clinical samples","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2015.12.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}